309 related articles for article (PubMed ID: 26014385)
21. Regulation of physiologic actions of LRRK2: focus on autophagy.
Ferree A; Guillily M; Li H; Smith K; Takashima A; Squillace R; Weigele M; Collins JJ; Wolozin B
Neurodegener Dis; 2012; 10(1-4):238-41. PubMed ID: 22204929
[TBL] [Abstract][Full Text] [Related]
22. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth.
Kawakami F; Yabata T; Ohta E; Maekawa T; Shimada N; Suzuki M; Maruyama H; Ichikawa T; Obata F
PLoS One; 2012; 7(1):e30834. PubMed ID: 22303461
[TBL] [Abstract][Full Text] [Related]
23. The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm.
Esteves AR; G-Fernandes M; Santos D; Januário C; Cardoso SM
Mol Neurobiol; 2015 Dec; 52(3):1804-1820. PubMed ID: 25394383
[TBL] [Abstract][Full Text] [Related]
24. ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.
Zhu Y; Wang C; Yu M; Cui J; Liu L; Xu Z
Protein Cell; 2013 Sep; 4(9):711-21. PubMed ID: 27023913
[TBL] [Abstract][Full Text] [Related]
25. The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity.
Lichtenberg M; Mansilla A; Zecchini VR; Fleming A; Rubinsztein DC
Cell Death Dis; 2011 Aug; 2(8):e196. PubMed ID: 21866175
[TBL] [Abstract][Full Text] [Related]
26. Designing antibodies against LRRK2-targeted tau epitopes.
Hamm M; Ladd TB; Levites Y; Golde TE; Giasson BI; Lewis J
PLoS One; 2018; 13(9):e0204367. PubMed ID: 30261006
[TBL] [Abstract][Full Text] [Related]
27. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation.
Miklossy J; Qing H; Guo JP; Yu S; Wszolek ZK; Calne D; McGeer EG; McGeer PL
Acta Neuropathol; 2007 Sep; 114(3):243-54. PubMed ID: 17639429
[TBL] [Abstract][Full Text] [Related]
28. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.
Melrose HL; Dächsel JC; Behrouz B; Lincoln SJ; Yue M; Hinkle KM; Kent CB; Korvatska E; Taylor JP; Witten L; Liang YQ; Beevers JE; Boules M; Dugger BN; Serna VA; Gaukhman A; Yu X; Castanedes-Casey M; Braithwaite AT; Ogholikhan S; Yu N; Bass D; Tyndall G; Schellenberg GD; Dickson DW; Janus C; Farrer MJ
Neurobiol Dis; 2010 Dec; 40(3):503-17. PubMed ID: 20659558
[TBL] [Abstract][Full Text] [Related]
29. LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.
Bae EJ; Kim DK; Kim C; Mante M; Adame A; Rockenstein E; Ulusoy A; Klinkenberg M; Jeong GR; Bae JR; Lee C; Lee HJ; Lee BD; Di Monte DA; Masliah E; Lee SJ
Nat Commun; 2018 Aug; 9(1):3465. PubMed ID: 30150626
[TBL] [Abstract][Full Text] [Related]
30. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
31. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
[TBL] [Abstract][Full Text] [Related]
32. Physiological and pathological functions of LRRK2: implications from substrate proteins.
Araki M; Ito G; Tomita T
Neuronal Signal; 2018 Dec; 2(4):NS20180005. PubMed ID: 32714591
[TBL] [Abstract][Full Text] [Related]
33. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß.
Lin CH; Tsai PI; Wu RM; Chien CT
J Neurosci; 2010 Sep; 30(39):13138-49. PubMed ID: 20881132
[TBL] [Abstract][Full Text] [Related]
34. Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model.
Castro-Sánchez S; Zaldivar-Diez J; Luengo E; López MG; Gil C; Martínez A; Lastres-Becker I
Neurobiol Aging; 2020 Dec; 96():148-154. PubMed ID: 33007689
[TBL] [Abstract][Full Text] [Related]
35. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
36. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
[TBL] [Abstract][Full Text] [Related]
37. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
Santos-Rebouças CB; Abdalla CB; Baldi FJ; Martins PA; Corrêa JC; Gonçalves AP; Cunha MS; Borges MB; Pereira JS; Laks J; Pimentel MM
Genet Test; 2008 Dec; 12(4):471-3. PubMed ID: 19072560
[TBL] [Abstract][Full Text] [Related]
38. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
[TBL] [Abstract][Full Text] [Related]
39. Wild-type and mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2) associate with subunits of the translocase of outer mitochondrial membrane (TOM) complex.
Neethling A; Engelbrecht L; Loos B; Kinnear C; Theart R; Abrahams S; Niesler T; Mellick GD; Williams M; Bardien S
Exp Cell Res; 2019 Feb; 375(2):72-79. PubMed ID: 30597143
[TBL] [Abstract][Full Text] [Related]
40. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
